From IV to oral: clinical outcomes in Staphylococcus aureus osteomyelitis
- 1Harborview Medical Center, 325 Ninth Ave, Box #359930, Seattle, WA 98104 USA
- 2Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, WA USA
Abstract
Background: Outcomes for patients receiving oral antibiotics for Staphylococcus aureus (SA) osteomyelitis, including methicillin-resistant SA (MRSA), are poorly characterized. We evaluated outcomes in patients treated with partial oral therapy at a public safety-net hospital.
Methods: We identified osteomyelitis cases among hospitalized adults where SA was isolated from microbiologic specimens from 6/30/2021–6/30/2024. Demographics and event dates were extracted via electronic query. Osteomyelitis diagnosis (first episode per anatomic site) was confirmed by chart review. Hardware presence, comorbidities, antibiotic usage, and outcomes were collected. Clinical failure was defined as either readmission due to therapy adverse effect or infection within 90 days post-discharge, or as loss to follow-up (LTFU). Using logistic regression, variables associated with clinical failure were identified.
Results: 248 individuals with SA (40.3% MRSA) osteomyelitis were identified, including patients with retained hardware (63.3%), recent substance use (36.7%), and housing instability (19.4%). Most individuals (97.1%) received initial intravenous (IV) therapy (median 11 days [IQR 5,17]). Patients with retained hardware (OR 1.50; CI 0.85–2.72) and bacteremia (OR 5.10; CI 2.85–9.27), were more likely to receive greater than two weeks of IV therapy; neither of which was associated with clinical failure. Fifty-two individuals (20.9%) required a change in antimicrobial therapy (alternative oral or IV agent). The majority (51/79, 64.5%) of clinical failures among 79 patients were attributed to loss to follow up. MRSA (OR 1.92; 95% CI, 1.04–3.55) and recent substance use disorder (OR 2.42; 95% CI, 1.25–4.70) were associated with clinical failure in the adjusted analysis.
Conclusion: In a high-risk SA osteomyelitis population treated with partial oral antibiotics, the majority (169/248, 68.1%) were treated successfully.
Trial registration: N/a.
Clinical trial number: Not applicable
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12879-026-14220-7.
Related
- From Heart Murmur to Bone Involvement: Tricuspid Valve Endocarditis With First-Rib Osteomyelitis in a Patient With Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia
- Torque Teno Virus Viremia in Complicated Staphylococcus aureus Infection: Prevalence, Viral Load, and Associations With Inflammatory Markers and Clinical Outcomes
- PF127 hydrogel-assisted in-situ Staphylococcus aureus biofilm fabrication endowing pathological animal model for chronic osteomyelitis
- Chlorhexidine MIC distribution, efflux pump gene profiles, and genotypic characteristics among clinical methicillin-resistant and methicillin-susceptible Staphylococcus aureus isolates
- Genomic Characterization of Clinical Staphylococcus aureus Isolates from Ecuador Reveals Diverse Lineages and Genomic Similarity Among Sequence Type 2625 Isolates
BibTeX
@article{beieler2026from,
title = {{From IV to oral: clinical outcomes in Staphylococcus aureus osteomyelitis}},
author = {Alison M. Beieler and Kristine F. Lan and Shireesha Dhanireddy and Chloe Bryson-Cahn and Audrey Li and Jeannie D. Chan and Whitney Hartlage and Preston Kramer and H. Nina Kim and Jason D. Simmons},
journal = {BMC Infectious Diseases},
year = {2026},
month = aug,
doi = {10.1186/s12879-026-14220-7},
url = {https://doi.org/10.1186/s12879-026-14220-7},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - From IV to oral: clinical outcomes in Staphylococcus aureus osteomyelitis
AU - Alison M. Beieler
AU - Kristine F. Lan
AU - Shireesha Dhanireddy
AU - Chloe Bryson-Cahn
AU - Audrey Li
AU - Jeannie D. Chan
AU - Whitney Hartlage
AU - Preston Kramer
AU - H. Nina Kim
AU - Jason D. Simmons
PY - 2026
DA - 2026/08/14
JO - BMC Infectious Diseases
DO - 10.1186/s12879-026-14220-7
UR - https://doi.org/10.1186/s12879-026-14220-7
AB - Background: Outcomes for patients receiving oral antibiotics for Staphylococcus aureus (SA) osteomyelitis, including methicillin-resistant SA (MRSA), are poorly characterized. We evaluated outcomes in patients treated with partial oral therapy at a public safety-net hospital. Methods: We identified osteomyelitis cases among hospitalized adults where SA was isolated from microbiologic specimens from 6/30/2021–6/30/2024. Demographics and event dates were extracted via electronic query. Osteomyelitis diagnosis (first episode per anatomic site) was confirmed by chart review. Hardware presence, comorbidities, antibiotic usage, and outcomes were collected. Clinical failure was defined as either readmission due to therapy adverse effect or infection within 90 days post-discharge, or as loss to follow-up (LTFU). Using logistic regression, variables associated with clinical failure were identified. Results: 248 individuals with SA (40.3% MRSA) osteomyelitis were identified, including patients with retained hardware (63.3%), recent substance use (36.7%), and housing instability (19.4%). Most individuals (97.1%) received initial intravenous (IV) therapy (median 11 days [IQR 5,17]). Patients with retained hardware (OR 1.50; CI 0.85–2.72) and bacteremia (OR 5.10; CI 2.85–9.27), were more likely to receive greater than two weeks of IV therapy; neither of which was associated with clinical failure. Fifty-two individuals (20.9%) required a change in antimicrobial therapy (alternative oral or IV agent). The majority (51/79, 64.5%) of clinical failures among 79 patients were attributed to loss to follow up. MRSA (OR 1.92; 95% CI, 1.04–3.55) and recent substance use disorder (OR 2.42; 95% CI, 1.25–4.70) were associated with clinical failure in the adjusted analysis. Conclusion: In a high-risk SA osteomyelitis population treated with partial oral antibiotics, the majority (169/248, 68.1%) were treated successfully. Trial registration: N/a. Clinical trial number: Not applicable Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12879-026-14220-7.
SN - 1471-2334
ER -